January 09, 2020 Verastem plays the Kras card For $3m Verastem adds to its pipeline another asset that a bigger company had given up on.
June 22, 2012 BIO 2012 – Could closer ties to payers help diagnostics? (Needs a tighter headline/lead JP)
